⏫ AI Designs ADHD Peptide In 24 Hours

The decentralized science project Bio Protocol and the PeptAI platform said they used AI to design OX2R-004, a peptide for the potential treatment of attention-deficit/hyperactivity disorder, in just 24 hours.

One hypothesis about the biology of ADHD is a deficit of orexins. These peptides (chains of amino acids) are produced in the hypothalamus and help regulate nervous system activity, circadian rhythms, and sleep-wake cycles. All existing drugs that act on orexin receptors are receptor antagonists (blockers) used to treat insomnia.

OX2R-004 was designed as an agonist, or activator, of the OX2R receptor. It is meant to mimic natural orexin and help stabilize the body's signaling, supporting communication between brain regions needed for concentration. There are currently no approved orexin receptor agonists on the market, while most clinical development in this area is focused on treating sleepiness and narcolepsy.

⚡️ Is This A Ready-Made ADHD Drug?

Not yet. For now, this is an early computational model, not a finished medicine, and the molecule still needs significant refinement. OX2R-004 breaks down too quickly, is unlikely to cross the blood-brain barrier, and may carry unwanted off-target risks.

However, without ML tools that helped predict the peptide's shape, receptor activity, toxicity, and other parameters, even this early work could have taken months. AI handled a significant part of that process in just one day.

Have you had any experience with ADHD?

🔥 — Yes
🤔 — No

@hiaimediaen